What is claimed is:

1. A compound having the structure:



wherein R_1 is hydrogen, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -NO_2, -CH_3, -CF_3, -$COCH_3$, -CO_2R_2, phenyl, phenoxy or straight chained or branched C_1-C_7 alkyl;

wherein R_2 is straight-chained or branched C_3-C_4 alkyl or cyclopropyl;

wherein R_3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, -NO_2, straight chained or branched C_1-C_7 alkyl;

wherein A is -H, -F, -Cl, -Br, -CN, -NO_2, -COR_3, -CO_2R_3, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein X is O or NH; and

wherein n is an integer from 0 to 5 inclusive.

2. The compound of claim 1, wherein R_1 is aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, $-NO_2$, $-COCH_3$, $-CO_2R_2$, straight chained or branched C_1-C_7 alkyl;

wherein R_3 is phenyl;

wherein A is H; and

wherein X is O.

3. The compound of claim 2, wherein R_2 is isopropyl.

4. The compound of claim 3, wherein the compound has the structure:



5. The compound of claim 3, wherein the compound has the structure:



6. The compound of claim 1, wherein R_1 is hydrogen, straight chained or branched C_1-C_7 alkyl; and wherein R_3

is aryl.

7. The compound of claim 6, wherein R_2 is isopropyl; and A is hydrogen.

8. The compound of claim 7, wherein the compound has the structure:



9. The compound of claim 7, wherein the compound has the structure:



10. A compound having the structure:



;

wherein R_1 is aryl or heteroaryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, $-NO_2$, $-OCH_3$, phenoxy, fused cyclopentanyl, straight chained or

branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein R_2 is straight-chained or branched C_1-C_4 alkyl or cyclopropyl;

wherein A is -H, -F, -Cl, -Br, -CN, -NO_2, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; and

wherein n is an integer from 1 to 5 inclusive.

11. The compound of claim 10, wherein R_1 is aryl optionally substituted with one or more -F, -Cl, -Br, -I or straight chained or branched C_1-C_4 alkyl; and

wherein A is H.

12. The compound of claim 11, wherein R_2 is isopropyl; and

wherein n is 2.

13. The compound of claim 12, wherein the compound has the structure:



14. The compound of claim 12, wherein the compound has the structure:



15. The compound of claim 12, wherein the compound has the structure:



16. The compound of claim 10, wherein R_1 is thienyl; and wherein A is H.

17. The compound of claim 16, wherein R_2 is isopropyl.

18. The compound of claim 17, wherein the compound has the structure:



19. A compound having the structure:



wherein W is



or



;

wherein each R_1 is independently hydrogen, methyl or ethyl;

wherein R_2 is straight-chained or branched C_3-C_4 alkyl or cyclopropyl;

wherein R_3 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -H, -F, -Cl, -Br, -I, -CN, $-NO_2$, straight chained or branched C_1-C_7 alkyl.

wherein each A is independently -H, -F, -Cl, -Br, -CN, $-NO_2$, $-COR_3$, $-CO_2R_3$, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein X is O, NR_3, CO or may be absent; and

wherein Y is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -I, -CN, $-NO_2$, straight chained or branched C_1-C_7 alkyl.

20. The compound of claim 19, wherein W is



;

and wherein X is O or may be absent.

21. The compound of claim 20, wherein R_2 is isopropyl.

22. The compound of claim 21, wherein the compound has the structure:



23. The compound of claim 21, wherein the compound has the structure:



24. The compound of claim 19, wherein W is



25. The compound of claim 24, wherein A is -H, -F, -Cl, -Br.

26. The compound of claim 25, wherein R_2 is isopropyl; and A is hydrogen.

27. The compound of claim 26, wherein the compound has the structure:



28. A compound having the structure:



wherein W is



or



wherein R_1 is hydrogen, straight chained or branched C_1-C_7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, $-NO_2$, $-OCH_3$, $-CO_2CH_3$, $-CF_3$, phenyl, straight chained or branched C_1-C_7 alkyl;

wherein R_2 is straight- chained or branched C_3-C_4 alkyl or cyclopropyl;

wherein A is -H, -F, -Cl, -Br, -CN, $-NO_2$, $-COR_1$, $-CO_2R_1$, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl.

wherein each B is independently -H, -F, -Cl, -Br, -I, -CN, $-NO_2$, $-COR_1$, $-CO_2R_1$, $-OCH_3$, $-OCF_3$, $-CF_3$, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein the aryl, phenoxy or benzyloxy is optionally substituted with one or more -F, -Cl, -Br, -CN, $-NO_2$, $-COR_1$, $-CO_2R_1$, $-OCH_3$, $-OCF_3$, $-CF_3$ or straight chained or branched C_1-C_7 alkyl.

29. The compound of claim 28, wherein W is



30. The compound of claim 29, wherein R_1 is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, $-NO_2$, straight chained or branched C_1-C_7 alkyl.

31. The compound of claim 30, wherein R_2 is isopropyl.

32. The compound of claim 31, wherein the compound has the structure:



33. The compound of claim 31, wherein the compound has the structure:



34. A compound having the structure:



wherein R_1 is hydrogen, straight chained or branched C_1-C_7 alkyl, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more -F, -Cl, -Br, -CN, $-NO_2$, $-CF_3$, $-OCH_3$, straight chained or branched C_1-C_3 alkyl;

wherein R_2 is straight-chained or branched C_3-C_4 alkyl or cyclopropyl;

wherein R_3 is -H, -F, -Cl, -Br, -I, -CN, $-NO_2$, $-CF_3$, -

OCH_3, or straight chained or branched C_1-C_3 alkyl, monofluoroalkyl or polyfluoroalkyl, or a phenyl ring fused to C_6 and C_7 of the indole moiety;

wherein R_4 is hydrogen or aryl optionally substituted with one or more -F, -Cl, -Br, -I, -CN, $-NO_2$, $-CF_3$, straight chained or branched C_1-C_3 alkyl;

wherein A is -H, -F, -Cl, -Br, -CN, $-NO_2$, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; and

wherein n is an integer from 2 to 4 inclusive.

35. The compound of claim 34, wherein R_3 is -H, -F, -Cl, -Br, -I, -CN, $-NO_2$, $-OCF_3$ or $-OCH_3$; and

wherein R_4 is hydrogen or phenyl optionally substituted with one or more -F, -Cl or $-CF_3$.

36. The compound of claim 35, wherein R_1 is hydrogen or phenyl optionally substituted with one or more -F, -Cl, -Br, -CN, $-NO_2$, $-CF_3$, $-OCH_3$ or straight chained or branched C_1-C_3 alkyl;

37. The compound of claim 36, wherein R_2 is isopropyl.

38. The compound of claim 37, wherein the compound has the structure:



39. The compound of claim 37, wherein the compound has the structure:



40. The compound of claim 37, wherein the compound has the structure:



41. A compound having the structure:



wherein each R_1 is independently hydrogen or CH_3;

wherein R_2 is straight-chained or branched C_1-C_4 alkyl or cyclopropyl;

wherein R_3 is benzyl or phenyl, wherein the benzyl or phenyl is optionally substituted with a methylenenedioxy group or one or more -F or -Cl;

wherein A is -H, -F, -Cl, -Br, -CN, $-NO_2$, straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

wherein X is $(CH_2)_2$, $COCH_2$ or CONH;

42. The compound of claim 41, wherein R_3 is phenyl optionally substituted with one or more -F; and

wherein A is hydrogen.

43. The compound of claim 42, wherein X is CONH.

44. The compound of claim 43, wherein R_2 is methyl.

45. The compound of claim 44, wherein the compound has the structure:



46. The compound of claim 44, wherein the compound has the structure:



wherein each Y is independently hydrogen or -F.

47. The compound of claim 46, wherein the compound has the structure:



48. The compound of claim 46, wherein the compound has the structure:



49. The compound of claim 41, wherein R_3 is benzyl optionally substituted with a methylenedioxy group or one or more -F or -Cl.

50. The compound of claim 49, wherein the compound has the structure:



wherein each Y is independently hydrogen or -F.

51. The compound of claim 50, wherein the compound has the structure:



52. A compound of claims 1 to 51, wherein the compound is enantiomerically pure.

53. A compound of claims 1 to 51, wherein the compound is diastereomerically pure.

54. The compound of claims 52 and 53, wherein the compound is enantiomerically and diastereomerically pure.

55. A pharmaceutical composition comprising a therapeutically amount of a compound of any of claims 1 to 51 and a pharmaceutically acceptable carrier.

56. The pharmaceutical composition of claim 55, wherein the amount of the compound is from about 0.01mg to about 500mg.

57. The pharmaceutical composition of claim 56, wherein the amount of the compound is from about 0.1mg to about 60mg.

58. The pharmaceutical composition of claim 57, wherein the amount of the compound is from about 1mg to about 20mg.

59.The pharmaceutical composition of claim 55, wherein the carrier is a liquid and the composition is a solution.

60. The pharmaceutical composition of claim 55, wherein the carrier is a solid and the composition is a tablet.

61. The pharmaceutical composition of claim 55, wherein the carrier is a gel and the composition is a suppository.

62. A process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of claims 1 to 51 and a pharmaceutically acceptable carrier.

63. A method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of the compound of any of claims 1 to 51.

64. The method of claim 63, wherein the therapeutically effective amount is between about 0.03 and about 1000 mg per day.

65. The method of claim 64, wherein the therapeutically effective amount is between about 0.30 and about 300 mg per day.

66. The method of claim 65, wherein the therapeutically effective amount is between about 1.0 and about 100 mg per day.

67. The method of claim 63, wherein the disorder is depression.

68. The method of claim 63, wherein the disorder is anxiety.

69. The method of claim 63, wherein the disorder is obesity.

70. The method of claim 63, wherein the disorder is urge incontinence.

71. A method of reducing the body mass of a subject, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to reduce the body mass of the subject.

72. A method of treating a subject suffering from depression, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's depression.

73. A method of treating a subject suffering from anxiety, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's anxiety.

74. A method of alleviating urge urinary incontinence in a subject suffering from an overactive bladder, which

comprises administering to the subject an amount of the compound of any of claims 1 to 51 effective to alleviate the subject's urge urinary incontinence.

74. A method of managing obesity in a subject in need of weight loss, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to induce weight loss in the subject.

75. A method of managing obesity in a subject who has experienced weight loss, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to maintain such weight loss in the subject.

76. A method of treating overactive bladder in a subject, which comprises administering to the subject an amount of a compound of any of claims 1 to 51 effective to treat the subject's overactive bladder.

78. A method of treating a disorder in a subject, wherein the symptoms of the subject can be alleviated by treatment with an MCH1 antagonist, wherein the MCH1 antagonist is the compound of any of claims 1 to 51.

79. A method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject an amount of an MCH1 antagonist effective to alleviate the symptoms, wherein the MCH1 antagonist is the compound of any of claims 1 to 51.